Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732559 | 0.83 | HTT (0.72) | HTTSMN1; SMN2TSHRALDH1A1CA12 | |
| SCHEMBL6993873 | 0.80 | CA12 (0.70) | HTTSMN1; SMN2TSHRCA12CA1 | |
| SCHEMBL14798746 | 0.79 | CA2 (0.49) | HTTSMN1; SMN2TSHRCA12CA1 | |
| SCHEMBL13296361 | 0.79 | HTT (0.76) | HTTSMN1; SMN2TSHRALDH1A1CA12 | |
| SCHEMBL966167 | 0.79 | HTT (0.61) | HTTSMN1; SMN2TSHRALDH1A1CA12 | |
| SCHEMBL3291832 | 0.78 | HTT (0.65) | HTTSMN1; SMN2TSHRALDH1A1CA12 | |
| SCHEMBL4506075 | 0.77 | HTT (0.77) | HTTSMN1; SMN2TSHRALDH1A1CA12 | |
| SCHEMBL1530297 | 0.76 | CNR2 (0.68) | HTTSMN1; SMN2TSHRALDH1A1CA12 | |
| SCHEMBL1695235 | 0.76 | NPC1 (0.66) | HTTSMN1; SMN2TSHRALDH1A1NPC1 | |
| SCHEMBL3194925 | 0.76 | SMN1; SMN2 (0.54) | HTTSMN1; SMN2TSHRALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | HTT 3376/4885SMN1; SMN2 3745/4885TSHR 2640/4885 |
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | HTT 3900/4885SMN1; SMN2 3845/4885TSHR 1577/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | HTT 3997/4885SMN1; SMN2 4093/4885TSHR 808/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | HTT 3900/4885SMN1; SMN2 3845/4885TSHR 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.